ClinConnect ClinConnect Logo
Search / Trial NCT00459004

Japanese Dose-Response Study of Rimonabant in Obese Patients

Launched by SANOFI · Apr 10, 2007

Trial Information

Current as of July 22, 2025

Completed

Keywords

Weight Loss

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Body Mass Index ≥25 kg/m²
  • Viceral Fat Area ≥ 100 cm²
  • Diet therapy for more than 8 weeks before start of the placebo observation period
  • Stable weight (variation \< ±3kg within 8 weeks before start of observation period)
  • At least 2 criteria of the following 3 comorbidities: Impaired Glucose Tolerance or Type 2 diabetes, Dyslipidemia (hypertriglyceridemia and/or low HDL-choresterol), Hypertension

About Sanofi

Sanofi is a global healthcare leader dedicated to empowering life through innovation in pharmaceuticals and vaccines. With a strong commitment to research and development, Sanofi focuses on addressing complex health challenges across various therapeutic areas, including diabetes, oncology, immunology, and rare diseases. The company leverages advanced science and technology to develop transformative therapies that improve patient outcomes. Through collaborative partnerships and a patient-centric approach, Sanofi strives to enhance global health and deliver sustainable solutions that meet the evolving needs of healthcare systems and communities worldwide.

Locations

Tokyo, , Japan

Patients applied

0 patients applied

Trial Officials

Kohji SHIRAI, Professor

Principal Investigator

Toho University Sakura Medical Center, Japan

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials